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Introduction
Seasonal influenza epidemics can affect 5%–10% of  adults, causing up to 0.5 million deaths annually 
worldwide (1). The most severe disease occurs in those with diverse factors associated with a suboptimal 
immune response, for example, children under 5 years of  age, the elderly, those who are pregnant or on 
immunosuppressants, or those with haematological malignancies. Every year, and particularly in novel 
outbreaks, there is also a small, distinct group of  previously healthy young adults (less than 50 years old) 
who succumbs to severe disease to the point of  requiring ventilatory support. Indeed, during the 2009 
pandemic (pH1N1), although most individuals infected with pH1N1 influenza A virus (IAV) had mild or 
uncomplicated illness, there was a discrete prevalence of  severe disease in otherwise healthy persons. In 
fact, 90% of  all deaths in the pandemic occurred in those under 65 years of  age (2–4). An “immune storm” 
has been suggested to underlie these severe cases, but the critical cellular immune cause remains unclear.
In each influenza season, a distinct group of young, otherwise healthy individuals with no risk 
factors succumbs to life-threatening infection. To better understand the cause for this, we 
analyzed a broad range of immune responses in blood from a unique cohort of patients, comprising 
previously healthy individuals hospitalized with and without respiratory failure during one 
influenza season, and infected with one specific influenza A strain. This analysis was compared 
with similarly hospitalized influenza patients with known risk factors (total of n = 60 patients 
recruited). We found a sustained increase in a specific subset of proinflammatory monocytes, 
with high TNF-α expression and an M1-like phenotype (independent of viral titers), in these 
previously healthy patients with severe disease. The relationship between M1-like monocytes 
and immunopathology was strengthened using murine models of influenza, in which severe 
infection generated using different models (including the high-pathogenicity H5N1 strain) was 
also accompanied by high levels of circulating M1-like monocytes. Additionally, a raised M1/M2 
macrophage ratio in the lungs was observed. These studies identify a specific subtype of monocytes 
as a modifiable immunological determinant of disease severity in this subgroup of severely ill, 
previously healthy patients, offering potential novel therapeutic avenues.
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The mechanisms by which influenza infections cause severe disease are complex and often multifacto-
rial, involving host and viral factors, and secondary bacterial infection (5–8). A cytokine-mediated inflam-
matory response has been shown to cause organ injury and influenza sepsis syndrome, and high levels of  
TNF-α, IL-6, KC, and MCP-1 are established causes of  lung pathology in murine models (6). NK responses 
and neutrophils, both critical for immune protection, can also contribute to pulmonary inflammation during 
severe infection (9). Improper contraction or excessive production of  TNF-α from antigen-specific CD8 T 
cells and high levels of  antigen-specific CD4 T cells and IL-17 have also been shown to correlate with immu-
nopathology (10, 11). However, the cause of  severe infection, specifically in young previously healthy adults, 
remains unknown, in part because of  their relative low frequency during an influenza season. In outbreaks 
involving novel strains of  the virus, such as the H5N1 outbreak in 2010, younger adults were disproportion-
ately affected and reported to have marked hypercytokinemia (12). However, it is unclear whether this is the 
case for all patients with severe influenza or if  this was specific to these young previously healthy individuals.
A pandemic provides the opportunity to study a large number of  patients. This larger group can then 
be separated into subsets of  patients with mild and severe disease and those with and without risk factors. 
This allows us to identify defining immune features for our group of  interest. In this study, performed 
during the second wave of  the 2009 pandemic, an extensive range of  cellular immune responses in freshly 
isolated blood cells was analyzed at the point of  admission to hospital. These human findings were then 
further explored in murine models of  mild and severe infection. Our studies show that a TNF-αhi M1-like 
monocyte response is a key determinant of  disease severity in the young, previously well adults with severe 
infection. Murine studies suggest that these cells contribute to a raised lung M1/M2 macrophage ratio and 
immunopathology of  severe influenza.
Results
Monocytes and low-density granulocytes are significantly increased in previously healthy, young individuals with severe 
influenza. The Mechanisms of  Severe Acute Influenza Consortium (MOSAIC) was established to recruit 
patients with influenza-like illness hospitalized during the pandemic (2009–2010) and the postpandemic 
(2010–2011) periods of  the pH1N1 outbreak (13, 14). Recruitment occurred in 11 London and Liverpool 
hospitals in the United Kingdom, from which fresh blood obtained within 72 hours of  admission (time 
point 1 [TP1]) (Figure 1 and Table 1) was processed in one center (Oxford) for 78 cases. Samples from 
healthy noninfected controls were also sent in identical conditions. Disease severity was defined at the 
point of  sampling according to criteria agreed upon by the MOSAIC consortium and based on the degree 
of  respiratory compromise: grade 1, no respiratory compromise, i.e., normal oxygen saturation breathing 
room air; grade 2, respiratory compromise requiring supplemental oxygen with oxygen saturations ≤93% 
while breathing room air, with or without requirement for noninvasive mechanical ventilatory support; and 
grade 3, respiratory compromise requiring mechanical ventilatory support. We classified grade 1 as “mild” 
disease and grades 2 and 3 as “severe” disease.
All samples were analyzed fresh using flow cytometry for monocyte, neutrophil, NK, CD4, CD8, and 
CD8 effector T cell frequencies and IFN-γ ELIspot response to overlapping peptides of  the entire pH1N1 
proteome. Detailed definitions of  immune populations are found in Table 2 and Supplemental Figure 1 
(supplemental material available online with this article; https://doi.org/10.1172/jci.insight.91868DS1). 
Excess peripheral blood mononuclear cells (PBMCs) were cryopreserved for further use.
Of the 78 patients who presented with symptoms of  influenza, 60 had pH1N1 virus infection confirmed 
by PCR. Of these, 8 were excluded because of  HIV-1 coinfection and 9 did not pass quality control require-
Table 1. Demographics of patient subsets
WRF mild (n = 6) WRF severe (n = 8) NRF mild (n = 6) NRF severe (n = 12) Healthy controls (n = 12)
Days from first symptom — 
median (range)
6 (5–17) 14 (5–21) 14 (5–21) 13 (8–26) NA
Age in years — median (range) 40 (27–58) 52 (23–69) 44 (23–50) 38 (32–48) 32 (25–55)
Gender — male 2 4 2 7 7
BMI >30 0 0 2 (33%) 5 (42%) 1
Characterization of the different patient groups in this study. WRF, with risk factors; NRF, no risk factors.
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ments for sample analyses (see Figure 1 legend for details), leav-
ing 43 patients for our study.
We adopted two analytical approaches. First, we ques-
tioned which immune cells were significantly different between 
mild and severe patients in the whole cohort of  IAV-infected 
patients (n = 43). Then, we excluded those who were on corti-
costeroids and immunosuppressants at the point of  sampling, 
which could independently affect immune response, and divid-
ed the remaining patients into previously healthy individuals 
with no risk factors (NRF) (n = 18), referred to as the NRF 
group (Supplemental Table 1), and those with a variety of  risk 
factors for severe disease, e.g., pregnancy, hematological can-
cers, or asthma (n = 14), referred to as the with risk factors 
(WRF) group (Figure 1 and Table 1). We noted but did not 
segregate patients by BMI (Table 1).
An overview analysis of  the flow cytometry data revealed 
an excess of  large, granular cells in PBMCs from many 
pH1N1-infected patients (Figure 2A). These cells can be clas-
sified as being of  a monocytic (CD11b+CD14mid–hiCD15–) or 
neutrophilic (CD11b+CD14–CD15+) origin (Figure 2B). The 
large number of  CD15+ neutrophilic cells was unexpected, 
since classical neutrophils do not colocalize with mononuclear cells following PBMC isolation by density 
gradient. These low-density granulocytes (LDGs) have also been identified by others in PBMCs from 
patients with severe sepsis, cancer, and HIV-1 infection (15–17).
Examining these and the other cellular immune responses in all patients with confirmed pH1N1 
infection (n = 43), we found that monocytes and LDGs were the only significantly different immune 
populations between patients with severe and mild disease (Figure 2, C and D, and Table 2).
Viral burden (obtained from nasal swabs or nasopharyngeal aspirates 24 hours before TP1) was presented 
as “pfu/ml equivalents”, derived from a standard curve generated by seeding known amounts of  pH1N1 
RNA onto MDCK plaque assays.The severe group had a significantly higher viral load relative to the mild 
group, though no difference between NRF mild and NRF severe groups was seen (Supplemental Figure 2, A 
and B). Additionally, there was no relationship between viral load and when the samples were obtained (Sup-
plemental Figures 2, C–F). Neither monocytes nor LDG levels correlated with viral load (Figure 2, E and F).
When we divided the patients into mild and severe NRF and WRF groups, excluding those on corti-
costeroids and immunosuppressants, the significant differences in monocyte and LDG levels between mild 
and severe cases were only found in the group of  patients with NRF (Figure 2, G and H, and Supplemental 
Figure 3). This was also the case when monocytes and LDGs were analyzed as percentages of  live cells in 
PBMCs (Supplemental Figure 4, A and B).
Because patients were hospitalized at different time points after the onset of  symptoms, we ques-
tioned if  the observed increase in monocyte and LDG levels was related to the length of  time from 
infection. We found no correlation between monocyte or LDG levels and the length of  time from onset 
of  symptoms (r = 0.4; P = 0.11 and r = 0.3; P = 0.25, respectively, rank-sum correlation test). Impor-
Figure 1. Flow chart of patient recruitment and grouping. 
All patients with suspected influenza A virus (IAV) infection 
(influenza-like symptoms) were sampled at TP1. aTechnical quality 
control (QC) required that all samples were processed without any 
freeze-thaw cycles, all baseline “fluorescence minus one” FACS 
controls were present, and control fluorochromes were at the 
expected intensity on the day of acquisition. bComorbidities in the 
study were hematological malignancies, asthma, chronic obstruc-
tive pulmonary disease (COPD), diabetes mellitus, cardiac failure, 
ischemic heart disease, and cancers. Patients with hypertension 
were not excluded. TP, time point; WRF, with risk factors; NRF, no 
risk factors.
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tantly, when standardizing for time from first symptoms by examining a subset of  patients sampled at 
similar points from first symptoms (n = 6 NRF mild patients [range: 8–18 days; average 11.6 days] and 
n = 5 NRF severe patients [range: 8–17 days; average 12.2 days]), we again observed a similar increase 
in numbers of  monocytes and LDGs in severe NRF patients only (Figure 2, I and J).
Figure 2. Sustained increase in monocyte levels in NRF patients with severe IAV infection. (A) Typical flow cytometry size-granularity plots from a severe 
pH1N1 and an ILI patient demonstrating excess of large, granular immune cell populations (gates “a” and “b”) for IAV-infected patients. ILI, influenza-like 
illness but PCR negative for influenza virus. (B) Gate “a” from A was identified as CD15+CD14– low density granulocytes (LDG) and gate “b” comprised CD14+ 
(CD14mid–hi) monocytes. Gate “b” can further be divided into CD14hiCD16– classical monocytes: “i”; CD14hiCD16+ intermediate or inflammatory monocytes, “ii”; 
and CD14midCD16+ nonclassical or patrolling monocytes, “iii.” These gates were CD3–. (C and D) Circulating CD14+ (i.e., CD14mid–hi) monocytes and CD15+ LDG 
expressed as absolute numbers of cells per ml of blood for all pH1N1 patients (n = 43; n = 17 mild, n = 26 severe) and healthy controls (n = 12). (E and F) Rela-
tionship between viral load at TP0 (see Table 1) and circulating monocytes and LDG for 41 of 43 pH1N1 patients (viral load unavailable for 2 patients). Viral 
load relative to each patient was expressed as “relative PFU equivalents” (see Methods). (G and H) Number of circulating CD14+ monocytes and CD15+ LDG 
for NRF (no risk factors; n = 18) and WRF (with risk factors; n = 14) patients. (I and J) Monocyte and LDG numbers for n = 5 severe and n = 5 mild NRF patients 
normalized for time from the first symptoms. These patients were sampled between 8 and 18 days from the first symptoms. (K) Monocyte and LDG num-
bers at TP1 (admission) and 4–6 weeks later (TP2) for n = 9 patients from the NRF severe group. Filled symbols refer to patients still hospitalized at TP2. 
r values and significance were calculated using Spearman’s rank test. All values are mean ± SEM for normally distributed sets and median ± interquartile 
range for nonnormal distribution. P values were calculated using Kruskal-Wallis test and Dunn’s multiple comparison test (C, D, G, and H); Mann-Whitney (I 
and J); and Wilcoxon matched-pairs signed rank test for TP1 versus TP2 (K). *P < 0.05; **P < 0.01; ****P < 0.0001. TP, time point; HC, healthy control.
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Figure 3. Monocytes in severe NRF patients are M1 like. (A–C) Classical, inflammatory, and patrolling monocytes in blood of mild and severe NRF and 
WRF patients. (D) Pie chart representation of classical, inflammatory, and patrolling monocyte frequencies in blood of NRF or WRF patients and healthy 
controls (HC) observed in A–C. Values refer to % of total monocytes. (E) Ex vivo expression of genes associated with M1 and M2 macrophage differentia-
tion in CD14+ monocytes isolated from n = 10 NRF and n = 5 WRF patients with severe disease. Each gene is normalized to β-actin in the sample and then 
compared with the mean of the gene/β-actin of healthy controls (n = 9) (Mann-Whitney test with Bonferroni correction for multiple testing; ** adjusted 
P = 0.01). (F) TNF-α gene expression normalized to CD14 gene expression for each of the severe NRF and WRF patients and healthy controls. (E and F) 
Asterisks refer to statistically different genes comparing NRF severe and WRF sever. (G) TNF-α/IL-10 gene expression. (H) Ratio of TNF-α/IL-10 protein 
expression by intracellular cytokine staining. TNF-α and IL-10 expression (as cytokine-positive cells, as proportion of CD14+ monocytes) was measured 
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Nine patients from the NRF group with severe disease consented to an additional blood sample 4–6 
weeks after acute sampling (TP2), providing paired comparisons. There was no significant difference in 
monocyte levels between TP1 and TP2 (Figure 2K). Patients who were still hospitalized at TP2 had a sig-
nificantly higher percentage of  monocytes than those who had been discharged (Supplemental Figure 4C). 
In contrast, LDG levels were markedly decreased at TP2 (Figure 2K and Supplemental Figure 4D).
As more patients in the NRF group had increased BMI compared with the WRF group, we also ques-
tioned if  BMI influenced the monocyte and LDG distribution in the group but did not find any significant 
association between these parameters or with severity (Supplemental Figure 4, E–I). Monocyte, but not 
LDG, levels remained significantly increased in NRF severe group when those with BMI >30 were exclud-
ed from analyses (Supplemental Figure 4, J and K)
Together, these results reveal that high levels of  circulating monocytes and LDGs (independent of  viral 
load) defined the immune profile of  young previously healthy patients with severe disease. However, only 
high levels of  monocytes were sustained in severe disease, while high levels of  LDGs were specific to the 
earliest period of  infection and returned to normal after this period (even in patients who remained ill).
Monocytes from severe NRF patients show M1-like features. We next determined whether the increased 
numbers of  monocytes from severe NRF patients corresponded to a particular phenotype. We first exam-
ined the frequencies of  the well-characterized monocyte subsets: classical (CD14hiCD16–), intermediate or 
inflammatory (CD14hiCD16+), and nonclassical or patrolling (CD14midCD16+) (18). There was a significant 
increase in the inflammatory subset in severe NRF patients, with a corresponding reduction in classical 
monocytes when compared with mild NRF and healthy controls (Figure 3, A–C). However, the inflamma-
tory subset was small relative to the classical subset and made up less than 10% of  monocytes for all groups 
(Figure 3D). We therefore hypothesized that there may be further differences, possibly within the classical 
subset, that were not captured by this division. Since macrophages can be classified as M1 or M2 according 
to specific surface markers secondary to IFN-γ/LPS or IL-4/IL-13 activation respectively (19), and since 
we have previously shown that some M1 and M2 features are conserved between circulating monocytes 
and tissue macrophages (20), we explored the use of  M1 and M2 markers as a method of  characterizing 
monocytes before they differentiate into macrophages. In the first step, we isolated CD14+ monocytes by 
positive MACS bead isolation from stored PBMCs of  10 severe NRF and 5 severe WRF patients (there 
were insufficient cells stored for the mild patients) and 9 of  the healthy controls (all isolated and stored 
with identical methods) and examined ex vivo expression of  11 genes related to the M1 (IL6, TNFA, IDO1, 
GBP1, CXCL10, and IL12B) and the M2 (TGM2, IL10, CD206, CD200R, and CD163) macrophage subsets, 
selected from the recent macrophage activation guidelines (21).
Monocytes from severe NRF and severe WRF groups showed higher expression of  some M1 (TNFA, 
CXCL10, and GBP1) genes compared with healthy controls (Figure 3E). TNFA was significantly increased 
in severe NRF compared with the severe WRF group. This was also the case when TNFA was normalized 
to CD14 levels (Figure 3F). All but one of  the M2 genes (CD163) were downregulated in the NRF severe 
patients compared with healthy controls (Figure 3E). However, the only significant difference between 
NRF severe and WRF severe groups was in TNFA expression. We then used TNFA and IL10 as functional 
representatives for M1 and M2 phenotypes, respectively, and found that the ratio of  TNFA to IL10 expres-
sion was markedly increased in the severe NRF group compared with the severe WRF group (Figure 3G).
We used the remaining stored samples (n = 11 NRF severe patients; no WRF samples were available) to 
validate the TNFA/IL10 gene expression ratio and to examine other representative surface protein levels for 
M1 (CCR7) and M2 (CD163) markers (21). The TNF-α/IL-10 protein ratio was increased in severe NRF 
patients compared with healthy controls by intracellular cytokine staining after 6 hours of  LPS stimulation, 
due to both high TNF-α and a reduction in IL-10 levels in NRF severe patients (Figure 3H and Supplemental 
Figure 5, A and B). CCR7 expression on monocytes from severe NRF patients was also increased compared 
with healthy controls, but CD163 expression was not (Figure 3, I and J). As no samples were available 
from patients with mild disease (NRF or WRF), it was not possible to surmise that the enhanced M1/M2 
ratio for severe NRF patients was not also found in mild NRF patients. However, even if  this were the case, 
the absolute numbers of  M1-like monocytes per ml in severe NRF is likely to be higher than that in mild 
following 6 hours of LPS stimulation of PBMCs. (I and J) Expression of M1 (CCR7 surface staining) and M2 (CD163 surface staining) markers on monocytes, 
measured by flow cytometry. P values were calculated using Kruskal-Wallis test and Dunn’s multiple comparison test for F–G and Student’s t test if data 
were normally distributed and Mann-Whitney test if not for A–D and H–J. *P < 0.05; **P < 0.01. NRF, no risk factors; WRF, with risk factors.
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Figure 4. Increased circulating monocytes in severe IAV infection is matched by high levels of monocyte-derived macrophages in lungs but 
reduced resident alveolar macrophages. (A) Appearance of lungs from day 4 of severe IAV infection (PR8) showing hemorrhagic areas. (B–G) Gating 
of monocytes and neutrophils in blood of mild and severe murine models: classical Ly6G+ neutrophils (i) and CCR2+Ly6ChiLy6G– monocytes (ii) (equiva-
lent to human CD14hi monocytes) on FACS plot of red cell–lysed blood on day 3 of mild (X-179A) and severe (PR8) IAV infection. Alveolar resident 
macrophages are CD11c+SiglecF+ and monocytes or MDMs in BAL are CCR2+. Populations of cells in BAL on day 3 after infection: Ly6CmidF4/80– neutro-
phils (i), Ly6ChiF4/80mid differentiating monocytes/monocyte-derived macrophages (MDM) (ii), and Ly6C– F4/80hi resident alveolar macrophages (iii). 
Positive expression was defined against FMO samples to accommodate autofluorescence. (H and I). Alveolar macrophages (iii) express M2 markers, 
while monocytes/MDMs (ii) express M1 markers and are low in M2 expression. (J–L) Absolute numbers of monocytes and neutrophils in blood and 
monocytes/MDMs and neutrophils in BAL and lung digests on day 3 (D3) after infection with X-179A (mild) or PR8 (severe) and uninfected mice. Find-
ings are from 2 experiments; n = 6 mice in total. Statistical comparison between monocytes and neutrophils in PR8 infection in J–L was performed 
separately and showed higher levels of monocytes/MDMs in BAL and lung digests compared with neutrophils (Mann-Whitney). (M and N) Number of 
Siglec F+ alveolar resident macrophages on day 3 in BAL and lung digests of mice. Statistical significance measured using 1-way ANOVA with Tukey 
test. Horizontal lines and error bars represent mean ± SEM for normally distributed sets and median ± interquartile range for nonnormal distribution. 
*P < 0.05; **P < 0.01; ****P < 0.0001. BAL, bronchoalveolar lavage; FMO, fluorescence minus one controls; AM, alveolar macrophages.
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NRF, given the significant differ-
ence in absolute monocyte numbers 
between these groups (Figure 2G). 
In 4 NRF severe patients, we had 
enough cells to test the difference 
between acute samples at TP1 and 
samples obtained 4–6 weeks later on 
TP2. For these patients, the TNF-α 
and IL-10 protein levels remained 
unchanged (Supplemental Figure 5, 
C and D), suggesting persistence, at 
least, of  the TNF-α and IL-10 intra-
cellular cytokine profile.
These findings show that 
monocytes in NRF patients with 
severe disease displayed signifi-
cantly increased TNF-α and a net 
M1-like phenotype compared with 
uninfected healthy controls and 
severe WRF patients.
Increased M1-like monocytes in 
blood of  severe IAV infection in mice 
is accompanied by high M1 monocyte-
derived macrophages in their lungs. To 
strengthen the findings from the 
human studies and to specifically 
explore the relationship between 
M1-like monocyte and macrophage 
profile in the lungs, we turned to 
murine models of  severe and mild influenza infection. This was particularly important, as we were ethi-
cally unable to sample the lungs of  patients with severe influenza. We first questioned if  M1-like monocytes 
were similarly raised in severe disease, and if  this increase is associated with high M1 monocyte-derived 
macrophages (MDMs) in the lungs.
Immune cells in blood, bronchoalveolar lavage (BAL), and digests of  unperfused lavaged lungs 
were examined in the early phase (day 3) of  a well-established severe IAV infection model (A/PR/8/34 
[PR8]) (Figure 4A and Supplemental Figure 6A) (22), compared with noninfected mice and those infect-
ed with a mild IAV (X-179A). X-179A–infected mice showed no change in weight loss and had signifi-
cantly (P = 0.004) lower lung viral titers compared with PR8 infection but were able to protect against 
secondary challenge with PR8 (Supplemental Figure 6, B and C), indicating that an immune response 
was mounted during primary challenge. We defined the monocytes/MDM spectrum in blood, BAL, 
and lung digests as CCR2+Ly6ChiLy6G–F4/80–/mid cells, and the neutrophil and alveolar resident mac-
rophages as Ly6G+Ly6ChiF4/80– cells and Ly6C–F4/80+CD11c+Siglec F+ cells, respectively (23) (Figure 
4, B–G). M1 macrophages were defined as CD86+Ly6Chi cells and M2 macrophages as CD206+Ly6Chi 
cells, based on established reports (24, 25).
As with others (26), we observed that Siglec F+ alveolar resident macrophages bore an M2-like phe-
notype with high expression of  Dectin-1 and CD206 (Figure 4H), in contrast to infiltrating Ly6Chi mono-
cytes/MDMs, which were M1 like, with increased expression of  CD86 but low Dectin-1 and CD206 
expression (Figure 4I).
Similar to our findings in humans, monocytes and neutrophils in the blood were significantly increased 
in severe infection compared with mild infection (Figure 4J). This was accompanied by high levels of  mono-
cytes/MDMs and neutrophils in the BAL and lung digests (Figure 4, K–L); however, in the lungs, mono-
cyte/MDM levels were in excess of  those of  neutrophils (Figure 4, K and L). In contrast to monocytes/
MDMs, alveolar resident macrophages in severe disease were significantly reduced compared with mild 
infection on day 3 of  infection (Figure 4, M and N).
Figure 5. Blood monocytes and lung monocyte/macrophages are M1 like. (A–C) Number of M1 and M2 
monocytes/MDMs on day 3 in blood, BAL, and lung digests. M1 monocytes were defined as CD86+Ly6Chi cells 
and M2 monocytes as CD206+Ly6Chi in appropriate gates from Figure 4, B–E. 2 experiments; n = 6 mice in total. 
(D and E) TNF-α production measured by flow cytometry intracellular cytokine staining after 6 hours of LPS 
in blood and ex vivo in lungs. Gated on Ly6Chi monocytes from blood. Statistical significance measured using 
1-way ANOVA with Tukey test. Horizontal lines and error bars in graphs represent mean ± SEM for normally 
distributed sets and median ± interquartile range for nonnormal distribution. *P < 0.05; **P < 0.01; ****P < 
0.0001. BAL, bronchoalveolar lavage; MDM, monocyte-derived macrophage.
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Figure 6. M2 macrophage transfer to lungs of infected mice improves disease outcome. (A) M1 and M2 markers on bone marrow–derived macrophages 
(MØ) used for adoptive transfer. Graphs show mean ± SEM from n = 3 preparations of bone marrow pooled from 4–6 mice per preparation. (B and C) Num-
ber of transferred cells (identifiable as CD45.1+ cells) in BAL and lung digests of mice 6 and 24 hours after administration of M1 BMDMs (+M1) or M2 BMDMs 
(+M2). n = 6 mice per group; 2 separate experiments. (Absolute values are given in Supplemental Figure 6, D and E.) (D) Numbers of resident alveolar mac-
rophages in host mice after M1 BMDM or M2 BMDM transfer. 2 experiments, total of 4–6 mice at each time point for B–D. (E–G) Weight loss, clinical scores, 
and percentage of mice culled after adoptive transfer of M1, M2 BMDMs, or PBS. Clinical course was best in the M2-transferred group compared with PBS 
or M1 groups, with statistically significant findings on days 3 and 4. On day 4, mice that received M1 showed significantly worse clinical scores compared 
with those that received PBS and M2: clinical score 0, healthy; 1, calm but still exploring; 2, slow and exploring less; 3, hunched and shivery; 4, inactive; 
and 5, inactive even with handling. Total of n = 6 mice per group, 2 experiments. Differences among the 3 groups were analyzed using 2-way ANOVA with 
repeated measures. Comparisons were performed up to day 4 when all 3 groups still had equal numbers of mice. All P values for multiple comparisons 
were <0.001 except for clinical score on day 3, where the P value for M2 compared with M1 and PBS P < 0.05. For A and D, statistical significance was mea-
sured using 1-way ANOVA with Tukey test. *P < 0.05; **P < 0.01; ***P < 0.001. BMDM, bone marrow–derived macrophage.
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Similar to humans, monocytes and MDMs in blood 
of  mice with severe disease showed a significantly higher 
M1/M2 phenotypic ratio (Figure 5A). This was matched 
by a high M1/M2 phenotypic ratio in the monocyte/
MDM cells in BAL and lung digests of  mice with severe 
infection compared with those with mild infection (Fig-
ure 5, B and C). LPS-induced TNF-α production by blood 
monocytes was significantly higher in mice with severe 
disease (Figure 5D). This was matched by increased ex 
vivo production of  TNF-α from monocytes/macrophages 
in lungs of  PR8-infected mice (Figure 5E) although this 
did not reach statistical significance.
These data show that, as in human disease, M1-like 
circulating monocytes were increased in the acute phase 
of  severe disease in mice. This was matched by high M1 
monocytes/MDMs in the lungs. Alveolar resident macro-
phages with an M2 phenotype were rapidly depleted in the 
acute period of  severe but not mild infection, amplifying 
the M1/M2 macrophage ratio.
Transfer of  M2 macrophages to lungs during the acute phase 
of  severe IAV infection reduces disease severity and improves out-
come. We next questioned whether increasing M1 or M2 
macrophages during the early periods of  infection altered 
immunopathology. We generated M2 bone marrow–
derived macrophages (BMDMs) from CD45.1+ C57BL/6 
mice by culturing bone marrow cells in M-CSF for 6 days 
and then with IL-4 and IL-13 (M2) for the final 24 hours. 
As a comparator, M1 BMDMs were adoptively transferred 
in another group of  mice. M1 BMDMs were generated by 
culturing bone marrow cells with IFNg rather than IL- 4 and IL- 13. BMDMs were >95% F4/80+. M1 and 
M2 BMDMs showed increased CD86 or CD206 and Dectin-1 expression, respectively (Figure 6A).
2 × 106 M1 BMDMs, M2 BMDMs (suspended in PBS), or PBS alone were administered intranasally to 
PR8-infected CD45.2+ C57BL/6 mice 1 day after IAV inoculation. Successful BMDM transfer was shown 
by presence of  CD45.1+ cells among CD45.2+ host cells, observed in BAL and digests of  lavaged lungs at 
the sixth and twenty-fourth hour after transfer (Figure 6, B and C, and Supplemental Figure 6, D and E). 
M2 macrophage transfer was more successful than that with M1, with the transferred cells making up nearly 
20% of  live cells in BAL compared with approximately 10% for M1. This may be due to the higher apoptotic 
rate for IFN-γ–stimulated M1 BMDMs. Neither group of  transferred BMDMs was detectable in the lungs 
at 48 hours after BMDM transfer (i.e., by day 3 of  infection). M1 and M2 BMDM transfer did not alter the 
number of  host macrophages in BAL, which, in the first 2 days, consisted of  only Siglec F+ alveolar resident 
macrophages (Figure 6D). This meant that inadvertently, M2 BMDM transfer increased the M2/M1 ratio 
more than M1 BMDM transfer increased the M1/M2 ratio during the first few days of  infection.
Mice that received M2 BMDMs showed significantly less weight loss following infection (Figure 6E) and 
better clinical scores over 10 days (Figure 6F) compared with infected mice that received PBS or M1 BMDMs. 
Mice that received M2 BMDMs were strikingly different clinically than those that received M1 BMDMs — 
they were able to resist restraint, while M1 mice were sluggish, shivery, and showed little resistance to han-
dling. All mice that received M1 and PBS reached their 20% weight loss limit by days 6 and 7, respectively, 
and were culled, while 25% of mice that received M2 never reached the 20% weight loss limit (Figure 6G).
These findings show that increasing the M2 macrophage levels in the lungs during the acute phase 
of  severe infection improved disease course, supporting a role for M2 macrophages in modulation of  
immunopathology in severe IAV infection.
Lungs from mice with high-pathogenicity H5N1 infection show enrichment of  monocyte-related genes and high 
M1/M2 gene ratio. Finally, to strengthen our hypothesis that a high M1/M2 macrophage ratio is involved 
in lung immune pathology, we questioned if  these findings are also observed in another model of  severe 
Table 2. Cellular immune correlates to disease severity
Immune factors examined AMild vs. severe disease P
CD3+ T cells/ml blood NS
CD14+CD15– monocytes/ml blood *0.01
CD15+CD14– LDG/ml blood *0.03
CD56+CD16+/– NK/ml blood NS
CD14+ monocyte/CD3+ T cell ratio *0.01
CD15+ LDG/CD3+ ratio NS
NK/CD3+ ratio NS
CD4/CD8 T cell ratio NS
CD38+HLADR+CD8 effector T cells (% of CD8) NS
IFN-γ ELISPOT response to IAV peptidesB
pH1N1 HA NS
pH1N1 NA NS
pH1N1 NP NS
pH1N1 NS NS
pH1N1 PA NS
pH1N1 PB NS
pH1N1 M1/M2 NS
Comparison between mild and severe disease at point of sampling (TP1) was 
performed using Mann-Whitney test. Multiple hypotheses testing with false 
discovery rate was also performed but there was no significant adjusted P value for 
any parameters. The T cell profile comprised CD3+ T cells, CD4/CD8 T cell ratio (not 
significant; data not shown), effector CD8+ T cells (CD38+HLADR+), and IFN-γ ELISpot 
response to entire pH1N1/09 proteome (16-hour incubation with overlapping peptides 
of pH1N1/09 proteome). See also Supplementary Figure 3, A–I. An = 43 patients with 
pH1N1 infection. BOnly n = 36 samples were available for testing. *significant P values. 
NS: not significant.
 
Downloaded from http://insight.jci.org on April 25, 2017.   https://doi.org/10.1172/jci.insight.91868
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.91868
R E S E A R C H  A R T I C L E
influenza, that caused by a high-pathogenicity H5N1 IAV infection, which is associated with 60% fatal-
ity in humans (27). Three groups of  mice (n = 6 per group in category 4 biolab facilities) were inoculated 
intranasally with the low-pathogenicity IAV H1N1 (X-179A) (at 1 × 105 times the 50% egg infectious dose/
ml [EID50/ml]) per mouse), severe H5N1 (A/Vietnam/1203/2004) (at 1 × 10
5 EID50/ml per mouse), or 
PBS. As expected, H5N1-infected mice developed more severe disease, with higher lung viral loads com-
pared with X-179A–infected mice, despite the same inoculating dose (Supplemental Figure 7, A–C). Mice 
were sacrificed at day 0 (before infection) and day 3 and 5 after infection, whole lungs (without flushing or 
lavaging the lungs) were harvested from each mouse, and RNA was extracted for gene expression profiling.
We first examined the enrichment of  immune cellular gene ontology (GO) terms in lungs using the 
Gene Ontology enRIchment anaLysis and visuaLizAtion (GOrilla) tool (28) and relevant GO terms (Sup-
plemental Table 2). We found a marked polarization toward monocyte-related GO terms on day 3 of  
H5N1 infection, which remained skewed on day 5 (Figure 7A and Supplemental Table 2). In contrast, 
high polarization to monocytes only emerged on day 5 in X-179A infection. As the lungs were unperfused, 
these genes reflect expression in cells from blood within the lung vasculature, in addition to cells in the 
interstitium and alveolar space. This was complemented by upregulation of  all chemokine genes involved 
in monocyte recruitment on day 3 in H5N1 infection, whereas only two genes (CCL8 and CXCL10) were 
Figure 7. Lungs from high-pathogenicity H5N1 infection are enriched for monocytes and M1 genes, with downregulation of M2 genes. (A) Quantitative 
spider plot representation of the degree of enrichment of gene ontology (GO) terms for major immune cell subsets using the GOrilla online tool. Numbers 
represent enrichment scores. Granulocyte, regulation of granulocyte chemotaxis; Monocyte, regulation of monocyte chemotaxis; Macrophage, regulation 
of macrophage chemotaxis; B cell, regulation of B cell–mediated immunity; NK cell, regulation of NK cell–mediated immunity; T cell, positive regulation of 
α-β T cell activation. Days 3 and 5 refer to days after infection. (B and C) Expression of differentially regulated monocyte-attracting chemokines in lungs on 
days 3 and 5 after infection with H5N1 (black) or X179A (gray) relative to uninfected mice. (D and E) GSEA enrichment plots of M1 macrophage or M2 mac-
rophage genes in lungs from H5N1- or X179A-infected mice on day 3, showing M1 enrichment of upregulated genes on day 3 for both H5N1 and X179A. This 
indicates an overrepresentation of M1 genes in both infections on day 3. In contrast, there was an underrepresentation of M2 genes in H5N1 but not X179A. 
This is one of 4 gene sets used to interrogate M1 and M2 gene enrichment (GSE51466) (all 4 are shown in Supplemental Figure 8). Enrichment score refers 
to the degree to which the gene set is overrepresented at the top or bottom of the ranked input list of genes. n = 3 mice per group for gene arrays. NES, 
normalized enrichment score (adjusted for gene set size or multiple hypothesis testing). Red bold or blue text indicates statistically significant enrichment 
of genes on day 3 after infection or in uninfected lungs, respectively.
Downloaded from http://insight.jci.org on April 25, 2017.   https://doi.org/10.1172/jci.insight.91868
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.91868
R E S E A R C H  A R T I C L E
upregulated in X-179A infection at this time point (Figure 7B). By day 5, more of  these genes were upregu-
lated in mild disease but at lower levels than in H5N1 infection (Figure 7C).
Using gene set enrichment analysis (GSEA) (29), we then tested for enrichment of  M1- or M2-specific 
genes in H5N1 or X-179A infection compared with uninfected lungs. Four gene sets encompassing the 
different methods of  M1 and M2 activation were tested (Supplemental Table 3). Lungs from H5N1 and 
X-179A infection showed enrichment for genes associated with M1 macrophages on day 3 and 5 (Figure 7, 
D, and Supplemental Figure 8, A and B). However, H5N1-infected (but not X-179A–infected) mice showed 
significantly less involvement of  M2 genes when compared with uninfected mice (Figure 7, E), and Supple-
mental Figure 8, A and B) consistent with the loss of  M2-biased alveolar resident cells early in infection in 
the PR8 severe model (Figure 4, E, M, and N).
These findings show that, in comparison to other immune subsets, high and rapid expression of  mono-
cyte genes (possibly from cells carried by blood supplying the lungs), rather than neutrophils, and a high 
M1/M2 macrophage gene ratio in the lung, amplified by downregulation of  M2 genes, were distinctive 
features of  high-pathogenicity H5N1 virus infection. This provides further support for the link between 
high levels of  circulating monocytes (relative to neutrophils) and high M1/M2 ratio during acute phase of  
infection, with disease severity in IAV infection.
Discussion
Many of  those who die from influenza are debilitated by co-existing medical conditions, old age, are very 
young, pregnant or suffering from some other known predisposition. It is highly unusual for previously 
healthy individuals to suffer life-threatening influenza disease, but these patients form a distinct and under-
researched group. Of the 60 cases of  severe influenza that we now report, 18 (30%) were without known 
risk factors (NRF) and were most severely ill — all required mechanical ventilatory support. Although it 
is thought that this group of  severely affected, previously healthy adults is unique to pandemics, our study 
shows that, at least in the first postpandemic season, there was also a sizeable number of  these patients. 
Middle-aged, previously healthy patients are also more highly represented in novel infections like the H5N1 
and H7N9 outbreaks (30); although there are other factors at play in these outbreaks, for example, the high 
pathogenicity of  the virus. We took advantage of  the opportunity to study patients in the second wave of  a 
low-pathogenicity IAV (pH1N1/09) pandemic, which made it less likely that severe infection was caused by 
the novelty or the inherent pathogenicity of  the IAV strain. The study also benefitted from having enough 
patients to stratify into groups with and without risk factors and, within these, those with mild and severe 
influenza, allowing us to determine the immune profile unique of  those severe patients with NRF. We show 
that the ability to mount a particular type of  monocytic response (M1 like, TNF-αhi) is a key feature in severe 
IAV, which appear specific to these young previously healthy patients with severe disease. We note that there 
was a trend toward higher levels of  T cells recognizing pH1N1 HA, NA and NP in PBMC (Supplemen-
tal Figure 3, D–I). This did not correlate with viral load but rather with the ratio of  monocytes to T cells 
(Supplemental Figure 3J), so we speculate that presence of  higher levels of  monocytes may provide better 
antigen-presenting capacity in the assays. In fact, when effector CD8 T cells were examined, no differences 
were found between groups (Supplemental Figure 3C).
We also observed more females in the milder group (mild NRF and mild WRF) compared with the 
severe groups (Table 1) in our study. Gender differences in incidence, morbidity, and mortality have been 
discussed in a WHO report (31), which concluded that, on balance, morbidity is worse in childhood and 
old age for men and worse in middle age for women, possibly due to inclusion of  pregnant women in epide-
miology studies. In our NRF group, pregnancy was excluded, so the cohort supports the possibility that, in 
the NRF groups, severe disease occurred more commonly in male individuals. However, the small numbers 
preclude a robust interpretation.
The murine studies were important to strengthen our human findings, since we were constrained by 
the number of  patients we had within one season and within the consortium. A pathogenic role for tissue 
macrophages per se in severe IAV infection is already shown by other studies (32–36), and this was not the 
intention of  our murine studies. Rather, we questioned whether the high levels of  circulating monocytes 
found in severe human disease with all the incumbent limitations of  human studies (e.g., variation in days 
from infection) could be replicated in the cleaner murine studies. We also wanted to determine if  these 
monocytes were similarly biased toward an M1-like phenotype (since this has not been shown before in 
circulating monocytes) and whether this is matched by high M1 MDMs in the lungs. We can conclude that 
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high ratio of  M1/M2-like monocytes is a feature of  severe influenza infection and this is associated with 
high M1-like macrophages in the lungs.
The lung studies raised the potential significance of  another finding in causation of  severe disease — 
that of  a near depletion of  the M2-biased Siglec F+ alveolar resident macrophages in the early part of  the 
severe but not mild infection. This loss has been reported before, although not in the context of  its contribu-
tion as a M2 macrophage presence and not in direct comparison to milder models with lower viral loads 
(37). The murine studies did not allow for the kinetics of  these cells to be observed, so alveolar resident 
macrophages may also eventually be depleted in the mild model. Although the frequency of  Siglec F+ 
alveolar resident macrophages is low (Figure 4, M and N), their presence may modulate the immunopa-
thology of  infection by way of  having M2-like antiinflammatory properties (23). This study does not prove 
that the Siglec F+ macrophages are involved in improving outcome, merely that presence of  M2 BMDMs 
for a brief  point (in fact, just before the depletion of  M2-biased resident alveolar macrophages occurred) 
improved disease course. Soluble factors produced by these cells, possibly IL-10 (as observed by others) 
(38), may have an influence on the immune profile beyond this brief  period. Another possibility is that the 
transferred M2 macrophages increased phagocytosis of  virus-infected cells. We note that the M1 MDM 
transfer did not result in a significantly worse outcome, although the trend of  clinical scores and weight loss 
was toward worse disease. One explanation could be the lower numbers of  transferred M1 MDMs (Supple-
mental Figure 6, D and E), possibly due to the higher apoptotic rate of  these cells (39). Another possibil-
ity is the relatively low net increase in M1 macrophages provided by the transferred cells within a mouse 
system that already had very high levels of  M1 macrophages. Thus, although there was a clear association 
between high M1-like monocytes in the blood and high M1 macrophages in the lungs and disease severity, 
the limitations of  the M1 macrophage transfer meant that the murine study falls short of  showing that M1 
macrophages per se worsens disease.
We used the “M1” and “M2” nomenclature in our study but acknowledge that there are clear overlaps 
in phenotypes and many functional subtypes that are not covered by this categorization (40). However, they 
remain the most established method of  categorization, and we use it to provide a guide to the functional 
polarization of  macrophages in vivo where M1 are proinflammatory and M2 prorepair or antiinflammato-
ry. Large sets of  genes define these subtypes, and our choice of  surface phenotypic markers reflects accept-
ed representative markers for these subtypes (21, 24, 25). In mice, M2 surface markers are established, with 
CD206, Dectin-1, and CD163 being used together or singly in most publications in this area. M1 is less 
easy, particularly for representative surface markers rather than gene expression. We chose CD86 (as did 
others, refs. 24 and 25) because of  a well-designed study by Kigerl and colleagues (24) showing infiltration 
of  CD86+ (M1) tissue macrophages in vivo, along with gene expression profiling of  all M1 and M2 genes 
from landmark studies on M1 and M2 macrophages (40).
Our findings provide a cellular pathway for the so-called immune storm in these severely ill patients 
(12) and pinpoint a pathway that could potentially be targeted for immune-modulatory therapy. We note 
that both monocytes and LDGs were increased. However, we focused on the monocytes, as their numbers 
were still increased 4–6 weeks after acute infection (in patients who were still in hospital) (Figure 2K), 
providing a stronger correlate to severity. The identity of  the LDGs is also unclear; potentially, they are a 
mixture of  myeloid-derived suppressor cells (15, 41), immature neutrophils (17), activated neutrophils (42), 
and neutrophils undergoing NETosis, which have a lower density than neutrophils (43). Our murine stud-
ies subsequently showed that monocytes were more numerous than neutrophils in the lungs of  severe IAV 
infection (severe PR8 infection, as well as severe H5N1 infection.
In humans, no relationship was found between a high viral load and monocyte response. Our viral load 
values refer to the viral burden at the point of  admission and sampling for the cellular studies. These values 
are accurate to examince the relationship between viral burden (relative to other patients within the cohort 
sampling) and immune parameters, which were measured at the same time. They are likely but may not relate 
to, the initial viral load at the point of  infection. Within these limitations, the lack of  relationship between 
viral load and monocytic response suggest that host predisposition to a high monocytic response could be at 
play. This could be due to host genetic variants that increase the sensitivity of  monocytes to chemoattractants, 
such as CCL2 (44), or, as shown in our recent studies, polymorphisms in IFITM3, a virus restriction factor, 
which was associated with increased CCL2 levels, increased viral load, high levels of  monocytes, and severe 
disease (13, 45). Recently, polymorphisms in the TNF-α gene were found to be overrepresented in severe dis-
ease in a Mexican 2009 pandemic cohort (which comprised mainly patients with no comorbidities) (46) and 
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could be a cause of  the extremely high expression of  TNF-α in monocytes derived from severe NRF patients 
in our study. Direct contribution of  TNF-αhi monocytes to disease severity is strengthened by our murine find-
ings, in which circulating monocytes uniformly secreted more TNF-α protein upon ex vivo stimulation. This 
also resonates with findings from Aldridge et al., in which severe lung injury was observed in conjunction 
with high levels of  TNF-α/iNOS-producing DCs (47).
A role for monocytes in causation of  immune pathology in young previous healthy individuals is also 
supported by a recent community-based study utilizing a broader age range (4 weeks to 71 years). Here, 
Oshansky and colleagues showed that young age and nasal monocyte response correlated most strongly 
with disease severity (48). Infants and young children mounted a high innate immune response, with high 
levels of  monocytes in nasal lavage that were unrelated to viral load. Together with our findings specifically 
in young previously healthy adults, the data suggest that a relatively inexperienced adaptive immune system 
may be a stage for a larger, persistent innate immune response and that monocytes are the chief  players.
Increased monocyte levels are an eminently modifiable feature in humans, and ultimately this study 
concerns the identification of  such a pathway. CSF-1 receptor inhibitors (already in clinical trials) (49) can 
reduce differentiation to macrophages, and their use can be guided by monocyte levels, which can act as 
a biomarker and indicator for treatment. Nebulized corticosteroids used for many years by clinicians for 
asthmatics could also potentially be an M2 macrophage-inducing agent and be delivered specifically to the 
lungs. Our M2 BMDM transfer findings suggest only a small amount of  M2 macrophage in the lungs could 
change disease course. Adoptive transfer of  M2 macrophages, or reprogramming of  M1 macrophages 
toward M2, has successfully alleviated disease in other M1-biased conditions, such as obesity (50), RSV 
(51), and atherosclerosis (52). While multiple pathways are likely to be ultimately responsible for influenza 
pathogenesis, our study suggests that targeting macrophage reprogramming could be a useful therapeutic 
intervention during severe disease. While associated with pathogenesis, TNF-α neutralization has not been 
successful in influenza, and, in fact, targeting a single inflammatory mediator has often been met with little 
success (53). By targeting the macrophage polarization spectrum, multiple pathways could be altered with 
potentially greater and more specific effect.
Finally, we note that TNF-α was more highly expressed in circulating monocytes from the severe NRF 
group compared with the WRF group, highlighting TNF-αhi monocytes as a potential specific biomarker 
for this group. This is significant, as currently there are no predictors for life-threatening disease in other-
wise healthy people with influenza.
In conclusion, our studies identify increased M1-like monocytes as an important correlate of  dis-
ease severity in young previously healthy adult patients with life-threatening disease and suggest that this 
increase leads to raised M1/M2 macrophage ratio in the lungs and contributes to disease severity in these 
patients. This provides a possible mechanistic cause for severity in these patients, a potential early identifier 
and a modifiable immune pathway for therapeutic targeting.
Methods
Human IAV study design. Patients with pandemic influenza A/CA/07/09 (pH1N1) infection who required 
hospitalization in England between November 2010 and February 2011 were recruited via MOSAIC. 
Human sample size was not predetermined, as the study was designed to capture the largest possible popu-
lation of  a rare subset of  patients (previously healthy patients who required hospitalization) during the 
second wave of  the influenza pandemic. All blood samples (including healthy controls) were collected in 
sodium heparin tubes, placed in a BioJar with cool gel packs, and transported by courier immediately to 
Oxford, where they were processed within 4 to 6 hours of  venesection. All samples from MOSAIC were 
tested for pH1N1 by PCR.
Determination of  viral loads in humans. Molecular viral presence was determined from nasal swabs or 
nasopharyngeal aspirate obtained at hospital admission 24–48 hours before TP1 using diagnostic qRT-
PCR performed at West of  Scotland Specialist Virology Centre. Viral nucleic acid was extracted using the 
Qiagen MDx Biorobot automated extractor with the QIAamp Virus MDx Kit according to the manufac-
turer’s instructions. qRT-PCR reactions were set up to a total volume of  15 μl using the Qiagen One-Step 
RT-PCR kit, using primers (influenza A matrix [M] or pH1N1 neuraminidase [NA], ref. 24) as described 
previously (54) on an ABI Prism 7500 SDS real time platform (Applied Biosystems). Positive samples 
were confirmed by detection of  influenza A M or NA gene or rising serology titers where available. For 
viral load quantitation, we first derived the crossing threshold (Ct) value (at the inflexion spot of  the 
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sigmoid amplification curve to capture the point at which DNA amplification is exponential) performed 
in a batched assay as a relative expression of  viral burden against each sample. This was then measured 
against a standard curve of  Ct value to PFU/ml generated by measuring PFU when known amount of  
pH1N1 was inoculated in MDCK cells. The results are presented as “relative PFU equivalents,” the values 
being relative to each other in the batched assay.
IFN-γ ELISPOT assay. Following PBMC extraction, ex vivo ELISpot assays were performed on fresh 
cells using methods described previously (55). Plates were coated the day before with IFN-γ capture anti-
body (1-D1K; MabTech) at 10 μg/ml and blocked with RPMI/10% FCS. 2 × 105 PBMCs were added in 
duplicate to each well with peptides at a final concentration of  2 μg/ml. Plates were incubated for 18 to 
20 hours at 37°C. Culture media was used as a negative control, and 1 μg/ml PHA was used as a positive 
control. Results were expressed as spot-forming units per 106 PBMCs after background subtraction. For 
stimulation with pH1N1-specific peptides, sequences from the full A/CA/04/2009 proteome were split 
into overlapping peptides of  18–20 mers and divided into pools comprising HA, NA, NP, NS, PA, PB, and 
M. Only results derived from assays that passed the standard quality control of  an appropriate positive or 
negative control response and background that did not reduce clarity of  spot-forming units were used.
Flow cytometry. PBMCs were extracted using density gradient separation for same day flow cytom-
etry phenotyping. For surface antigen staining, cells were incubated for 20 minutes at 4°C in the dark 
with fluorochrome-conjugated mAbs in 96-well round-bottom plates in FACS buffer (PBS containing 
10% FCS and 1% BSA). For detection of  intracellular cytokines, cells were fixed following surface 
staining in 1% formaldehyde (Sigma-Aldrich) for 15 minutes at room temperature, washed, and incu-
bated for 30 minutes at 4°C in FACS buffer containing 0.5% Saponin (Sigma-Aldrich) and fluoro-
chrome-conjugated mAbs. Intracellular cytokine staining was performed on cells following a 6-hour 
incubation with or without 1 μg/ml LPS in both human and mouse studies. In human studies, 10 μg/
ml Brefeldin A was added for the last 4 hours of  culture. For TNF-α detection from mouse blood and 
lungs, Brefeldin A was included in all buffers used in sample in all buffers used in sample collection, 
processing and subsequent ex vivo stimulation.
In murine flow cytometry experiments, nonspecific antibody binding was corrected for using FC block 
(anti-CD16/32, eBiosciences). In both human and mouse studies, fluorescence minus one controls were 
used to identify positive populations and account for autofluorescence. Samples were acquired on a CyAn 
analyzer (Beckman Coulter) or a 4-laser configuration LSR-II (BD Biosciences) and analyzed using Flowjo 
V10 (Tree Star). In all instances, data analysis were performed on single live cells by gating out doublets and 
dead cells. All freshly acquired samples had greater than 98% viability.
Antibodies used are listed in Supplemental Table 4 (human) and Supplemental Table 5 (mouse).
qPCR. RNA was extracted from purified CD14+ MACS-isolated monocytes from defrosted PBMCs or 
from homogenized lung tissue from mice using TRIzol reagent (Ambion) and reverse transcribed to cDNA 
using the SuperScript III First-Strand Synthesis System (ThermoFisher Scientific), following the manufac-
turer’s instructions. qPCR assays were set up using SYBR Green master mix (ThermoFisher Scientific) and 
analyzed on the 7900HT Fast Real-Time PCR System with 384-well block module (human CD14+ mono-
cytes) or the 7500 Fast Real-Time PCR System (mouse lungs). Primer sequences for human monocytes are 
listed in Supplemental Table 6. Fold changes were analyzed using the 2–ΔΔCt method. Primers for influenza 
matrix gene in mice have been described previously (56).
Murine IAV models. Seven to eight-week-old female C57BL/6 (CD45.2) mice and B6SJL (CD45.1) 
mice were obtained from breeding pairs originally purchased from The Jackson Laboratory. Mice were 
randomly allocated to infection or control groups. Investigators were not blinded to group allocation 
but were unaware of  outcome (mild, severe, uninfected) during processing of  tissues and analysis by 
flow cytometry. All experiments were designed in keeping with the NC3R guidelines. IAV was admin-
istered to mice intranasally in a total volume of  40 μl as previously described (22). Influenza A (H1N1) 
X-179A, a A/California/07/2009 — A/Puerto Rico/8/34 reassortant, and influenza A (H5N1) A/
Vietnam/1203/2004 were all used at 1 × 105 EID50/ml. Influenza A (H1N1) A/Puerto Rico/8/34 
(PR8) was used at 1 × 105.35 EID50/ml (severe model) or 1 × 10
3.25 EID50/ml (macrophage transfer mod-
el) in the adoptive transfer experiments to reduce morbidity and cull rate for the model. PBS was used 
to inoculate “uninfected” mice. BAL was collected as previously described (22). Blood was collected in 
EDTA following cardiac puncture, and lungs were cut into 1-mm2 pieces and digested in Collagenase A 
(Roche) (1 mg/ml in PBS) and DNAse I (Sigma-Aldrich) (200 μg/lung) at 37°C.
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Murine macrophage generation and adoptive transfer. Macrophages were generated from bone marrow isolat-
ed from femurs and tibias of  7-week-old female B6SJL (CD45.1) mice by culturing in M-CSF (40 ng/ml) for 
6 days in 6-well low-adherence plates (Corning). After this, macrophages were differentiated over 24 hours 
in IFN-γ (10 ng/ml) for M1, IL-4 and IL-13 (10 ng/ml each) for M2, or nothing for M0. 2 × 106 differenti-
ated macrophages were then transferred intranasally to C57BL/6 (CD45.2) mice 1 day after PR8 infection.
Murine lung tissue microarray. Lungs were removed from euthanized mice, cut into 1-mm2 pieces and placed 
in RNAlater for RNA extraction using TRIzol reagent (Ambion). Lungs were homogenized using glass homog-
enizers and passed through a QiaShredder (Qiagen) for complete tissue disruption. 200 μl Chloroform was 
added to each sample to isolate the aqueous phase containing RNA, which was transferred to a new tube on 
ice. Isopropanol was added to precipitate RNA, and the RNA pellet was washed in 75% ethanol before resus-
pension in Nuclease-free water for quantification and quality assessment using Nanodrop and Agilent 2100 
Bioanalyzer instruments. Intact nondegraded RNA (RIN >8) was used. For microarray, GeneChip whole-
transcriptome (WT) target preparation was performed using the WT PLUS Reagent Kit (Affymetrix) following 
the manufacturer’s instructions, using 100 ng input RNA. Fragmented, labeled samples were hybridized onto 
Mouse Gene 1.0 ST Array chips, stained, and washed using the GeneChip Fluidics Station 450 and the fluo-
rescent signals were captured as data image files for analysis with the Affymetrix Gene Expression Console.
For H5N1 lungs, RNA samples from each group were pooled to comply with low handling protocol in 
category 4 laboratories and hybridized onto one cartridge. For X-179A lungs, each biological replicate was 
hybridized separately (n = 3). Both sets were compared with their own uninfected controls.
Microarray analysis. Microarray data were analyzed with Affymetrix Expression Console Software and 
R program (https://www.r-project.org/) to identify differentially expressed genes. Ranked gene lists were 
created between day 3 or day 5 H5N1 or X-179A lung samples and lungs from uninfected mice for GSEA 
(29) and GOrilla (28) analysis. For GOrilla analysis, GO terms related to monocytes, macrophages, B cells, 
T cells, NK cells, and granulocytes were examined. GSEA was performed using open source software 
(v5.0, Broad Institute, http://www.broadinstitute.org/gsea/index.jsp). Ranked gene lists were computed 
with genes highly expressed in M1 or M2 macrophages, identified from published data sets (NCBI’s Gene 
Expression Omnibus accession GSE35495, GSE32690, GSE63245, and GSE51466), which were analyzed 
with GE02R. For this, M1 macrophages were compared with M2 macrophages to identify genes exclu-
sively upregulated by either subset. Genes at adjusted P < 0.05 and logFC >1.5 were used for analysis. 
Where the number of  genes was above 500, the top 500 genes were used for input into GSEA. Lists of  
genes are included in Supplemental Table 7. GOrilla analysis was performed online (http://cbl-gorilla.
cs.technion.ac.il/) to identify significantly enriched GO terms, which are manually searched for terms relat-
ing to “monocyte,” “macrophage,” “neutrophil,” “granulocyte,” “T cell,” “B cell,” or “NK cell.” Heatmaps 
were created using Mev (http://mev.tm4.org/).
The data set and technical information according to the Minimum Information about a Microarray 
Experiment requirements are available at the Gene Expression Omnibus website (https://www.ncbi.nlm.
nih.gov/geo/; accession GSE70882).
Statistics. All statistical analysis was performed using GraphPad Prism 5.01 (GraphPad) or R program-
ming. Normality of  data distribution was first tested using the D’Agostino and Pearson omnibus normality 
test, and equality of  variance was examined using F test. Normally distributed data sets were compared 
using 2-tailed Student’s t test when comparing two groups or 1-way or 2-way ANOVA when comparing mul-
tiple groups. Where comparisons included data not normally distributed, the Mann-Whitney test was used 
to compare data sets. Where multiple data sets included data that were not normally distributed, Kruskal-
Wallis with Dunn’s multiple comparison post-test analysis was performed. All tests performed were 2 sided. 
Corrections for multiple comparisons in large data sets (Supplemental Table 2 and the gene expression data) 
are specified in legends for the data shown. A P value of  less than 0.05 was considered significant. Error bars 
on graphs represent SEM unless otherwise stated. During data analysis, investigators were unaware of  out-
come groups (mild, severe, healthy) for flow cytometry and ELISPOT studies until analysis was complete.
Study approval. The MOSAIC study was approved by the NHS National Research Ethics Service, Outer 
West London Research Ethics Committee, UK (09/H0709/52, 09/MRE00/67). All adult subjects pro-
vided informed consent, and a parent or guardian of  any child participant provided informed consent on 
their behalf. Informed consent was given in written form in all cases. Where the patient was incapacitated, 
“assent” from relatives, friends, or welfare attorneys was obtained in written form. This was approved by 
the Oxfordshire Research  Ethics Committee, UK.
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H5N1 mouse experiments were performed under substantial severity limit protocols approved by the 
Home Office under the auspices of  the UK Animal Scientific Procedures Act 1986 (PPL 30/2407) in spe-
cific containment facilities at the National Institute of  Medical Research, Mill Hill, under Specified Animal 
Pathogen Orders license PATH/57/2009/1 at biosafety level 4. For all other murine experiments, mice 
were maintained at the Biomedical Services Unit at the John Radcliffe Hospital (Oxford, UK) and were 
used according to established University of  Oxford institutional guidelines under the authority of  a UK 
Home Office project license. The Home Office project license for all experiments allowed up to 20% weight 
loss. Specific permission was given for H5N1 experiments where 35% weight loss was allowed.
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